Deciphering biology,
discovering new anti-infectives

through deep phenotypic insights and machine learning

The "silent pandemic" is no longer silent.
Antimicrobial resistance (AMR) leading to drug-resistant infections is now a recognized and growing global health crisis. The limited pipeline of new drugs to treat the increase in drug resistant infections is a significant global concern.

35,000

deaths annually in the U.S. from drug-resistant infections

Source: CDC

4,950,000

people who died in 2019 suffered at least one drug resistant bacterial infection and AMR directly caused 1.27 million of those deaths

Source: The Lancet

10,000,000

Unless action is taken, the burden of deaths from AMR could balloon to 10 million lives each year by 2050

Source: O'Neill Report

New classes of antibiotics are urgently needed to combat the rise of drug resistance.

Learn More

Discovering new classes of anti-infectives to overcome drug resistant infections.

Our machine learning (ML)-based imaging platform for anti-infective drug discovery enables rapid and highly efficient identification of compounds with new and unexploited mechanisms of action at the very outset of the discovery process.

Our combined expertise, cutting edge technologies and novel workflows enable a rapid and early understanding of a compound’s mechanism of action, the potential addressable target product profile, and clinical utility based on deep analysis of cell behavior.

Explore Platform

Delivering new classes of anti-infectives.

ArrePath is applying its technology platform to develop a pipeline of new classes of antibiotics,
targeting unexploited and under-exploited mechanisms of action, to address unmet clinical need and overcome drug resistance.

Discover Strategy